Antibiotic Resistance Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

The global antibiotic resistance market generated a revenue of approximately US$ 10.6 billion in 2024, and it is expected to reach a valuation of US$ 16.5 billion by the end of 2031. Antibiotic resistance (ABR) is a critical concern, primarily arising from inappropriate and uncontrolled antibiotic use, and it encompasses bacteria, fungi, parasites, and viruses.

Key Market Insights

Antibiotic resistance poses a significant global threat, affecting bacteria, fungi, parasites, and viruses. The misuse of antibiotics, including over-the-counter usage, contributes to the emergence of drug-resistant infections. Diseases like community-acquired pneumonia (CAP) and hospital-acquired infections remain leading causes of morbidity and mortality worldwide.

Market Growth Drivers

1. Prevalence of Drug-Resistant Infections: Emerging countries, particularly in Asia, are hotspots for the emergence and spread of antimicrobial resistance. Factors such as a large population, an aging demographic, urbanization, and limited healthcare access contribute to the susceptibility to antibiotic-resistant infections.

2. Introduction of Antibiotics Countering Resistance: The need for antibiotics that can counter antibiotic resistance has led to the development of new drugs, including Beta Lactum Antibiotics, Cephalosporins, Quinolones Antibiotics, Macrolide Antibiotics, Tetracyclines, and Oxazolidinones. These pharmaceuticals aim to address the growing challenge of antibiotic resistance.

3. Government and Public Health Initiatives: Various governments and non-profit organizations have launched initiatives to raise awareness about antibiotic resistance and improve access to affordable treatments. The Global Action Plan on ABR is a notable effort to address this global threat.

Challenges Impacting Market Growth

The high cost of treatment, particularly in developing regions, poses a significant challenge to addressing antibiotic resistance. Access to affordable drugs is crucial, but the increasing costs of prescription medicines make treatments unaffordable for many. Drug-resistant infections contribute to extended hospital admissions, leading to higher healthcare costs.

Booming U.S. Market

The United States has experienced significant growth in the antibiotic resistance market, primarily due to initiatives by government entities like the Center for Disease Control and Prevention (CDC). These efforts focus on raising awareness about antibiotic resistance and the importance of addressing this issue, driving market expansion.

Lucrative German Market

Germany is actively combating antibiotic resistance at both the national and international levels through the Federal Institute for Drugs and Medical Devices (BfArM). The development of novel antibiotics or combinations of active compounds is crucial to effectively treat bacterial illnesses in the future, contributing to the market's growth.

Prominent Japanese Market

Japan is emerging as a prominent market for antibiotic resistance, with a growing demand for a neutral platform to facilitate collaboration between businesses, ministries, academics, and the private sector. This collaborative approach aims to strengthen AMR countermeasures efficiently.

Competitive Landscape

Leading manufacturers are expanding their product lines globally by introducing technologically advanced items. Mergers, acquisitions, and firm collaborations are common tactics employed by competitors in the antibiotic resistance sector to enhance their offerings.

Key Companies Profiled:

Thermo Fisher Scientific, Inc.
Merck KgaA
Bio-Rad Laboratories, Inc.
Takara Bio, Inc.
QIAGEN N.V.
Pall Corporation
Eppendorf Corporate
Tarsons Products PVT. LTD.
Applied Biological Materials Inc.
Greiner AG
Brooks Life Sciences
Corning Incorporated
Cytiva
PerkinElmer

The global antibiotic resistance market is witnessing steady growth, driven by the urgent need to address drug-resistant infections and the introduction of antibiotics to combat resistance.

Market Segmentation

By Drug Class:

Beta Lactum Antibiotic
Cephalosporins
Quinolones Antibiotics
Macrolide Antibiotics
Tetracyclines
Oxazolidinones
Others

By Pathogen:

Staphylococcus aureus
Streptococcus pneumonia
Neisseria gonorrhoeae
Enterococcus faecium
Escherichia coli
Klebsiella Pneumonia
Shigella
Clostridium difficile
Others

By Disease:

Community Acquired Bacterial Pneumonia (CABP)
Hopitals Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
Complicated Urinary Tract Infections (CUTI)
Complicated Intra-Abdominal Infections (CIAI)
Blood Stream Infections (BSI)
Abdominal Infection and Diarohhea (Clostridium difficile infections (CDI) & Shigella)
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Drug Resistant Gonorrhoeae

By Mechanism of Action:

Cell Wall Synthesis Inhibitors
Protein Synthesis Inhibitors
DNA Synthesis Inhibitors
RNA Synthesis Inhibitors
Others

By Distribution channel:

Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Antibiotic Resistance Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Antibiotic Resistance Market Outlook, 2018 - 2031

3.1. Global Antibiotic Resistance Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Beta Lactam Antibiotic
  - 3.1.1.2. Cephalosporins
  - 3.1.1.3. Quinolones Antibiotics
  - 3.1.1.4. Macrolide Antibiotics
  - 3.1.1.5. Tetracyclines
  - 3.1.1.6. Oxazolidinones
  - 3.1.1.7. Others
3.2. Global Antibiotic Resistance Market Outlook, by Pathogen, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Staphylococcus aureus
  - 3.2.1.2. Streptococcus pneumonia
  - 3.2.1.3. Neisseria gonorrhoeae
  - 3.2.1.4. Enterococcus faecium
  - 3.2.1.5. Escherichia coli
  - 3.2.1.6. Klebsiella Pneumonia
  - 3.2.1.7. Shigella
  - 3.2.1.8. Clostridium difficile
  - 3.2.1.9. Others
3.3. Global Antibiotic Resistance Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Community Acquired Bacterial Pneumonia (CABP)
  - 3.3.1.2. Hospitals Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
  - 3.3.1.3. Complicated Urinary Tract Infections (CUTI)
  - 3.3.1.4. Complicated Intra-Abdominal Infections (CIAI)
  - 3.3.1.5. Blood Stream Infections (BSI)
  - 3.3.1.6. Abdominal Infection and Diarrhoea (Clostridium difficile infections (CDI) & Shigella)
  - 3.3.1.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  - 3.3.1.8. Drug Resistant Gonorrhoeae
3.4. Global Antibiotic Resistance Market Outlook, by Mechanism of Action, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. Cell Wall Synthesis Inhibitors
  - 3.4.1.2. Protein Synthesis Inhibitors
  - 3.4.1.3. DNA Synthesis Inhibitors
  - 3.4.1.4. RNA Synthesis Inhibitors
  - 3.4.1.5. Others
3.5. Others Global Antibiotic Resistance Market Outlook, by Distribution channel, Value (US$ Bn), 2018 - 2031
- 3.5.1. Key Highlights
  - 3.5.1.1. Hospitals Pharmacies
  - 3.5.1.2. Retail Pharmacies
  - 3.5.1.3. Online Pharmacies
3.6. Global Antibiotic Resistance Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.6.1. Key Highlights
  - 3.6.1.1. North America
  - 3.6.1.2. Europe
  - 3.6.1.3. Asia Pacific
  - 3.6.1.4. Latin America
  - 3.6.1.5. Middle East & Africa

4. North America Antibiotic Resistance Market Outlook, 2018 - 2031

4.1. North America Antibiotic Resistance Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Beta Lactam Antibiotic
  - 4.1.1.2. Cephalosporins
  - 4.1.1.3. Quinolones Antibiotics
  - 4.1.1.4. Macrolide Antibiotics
  - 4.1.1.5. Tetracyclines
  - 4.1.1.6. Oxazolidinones
  - 4.1.1.7. Others
4.2. North America Antibiotic Resistance Market Outlook, by Pathogen, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Staphylococcus aureus
  - 4.2.1.2. Streptococcus pneumonia
  - 4.2.1.3. Neisseria gonorrhoeae
  - 4.2.1.4. Enterococcus faecium
  - 4.2.1.5. Escherichia coli
  - 4.2.1.6. Klebsiella Pneumonia
  - 4.2.1.7. Shigella
  - 4.2.1.8. Clostridium difficile
  - 4.2.1.9. Others
4.3. North America Antibiotic Resistance Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Community Acquired Bacterial Pneumonia (CABP)
  - 4.3.1.2. Hospitals Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
  - 4.3.1.3. Complicated Urinary Tract Infections (CUTI)
  - 4.3.1.4. Complicated Intra-Abdominal Infections (CIAI)
  - 4.3.1.5. Blood Stream Infections (BSI)
  - 4.3.1.6. Abdominal Infection and Diarrhoea (Clostridium difficile infections (CDI) & Shigella)
  - 4.3.1.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  - 4.3.1.8. Drug Resistant Gonorrhoeae
4.4. North America Antibiotic Resistance Market Outlook, by Mechanism of Action, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. Cell Wall Synthesis Inhibitors
  - 4.4.1.2. Protein Synthesis Inhibitors
  - 4.4.1.3. DNA Synthesis Inhibitors
  - 4.4.1.4. RNA Synthesis Inhibitors
  - 4.4.1.5. Others
4.5. North America Antibiotic Resistance Market Outlook, by Distribution channel, Value (US$ Bn), 2018 - 2031
- 4.5.1. Key Highlights
  - 4.5.1.1. Hospitals Pharmacies
  - 4.5.1.2. Retail Pharmacies
  - 4.5.1.3. Online Pharmacies
- 4.5.2. BPS Analysis/Market Attractiveness Analysis
4.6. North America Antibiotic Resistance Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.6.1. Key Highlights
  - 4.6.1.1. U.S. Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 4.6.1.2. U.S. Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 4.6.1.3. U.S. Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 4.6.1.4. U.S. Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 4.6.1.5. U.S. Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 4.6.1.6. Canada Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 4.6.1.7. Canada Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 4.6.1.8. Canada Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 4.6.1.9. Canada Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 4.6.1.10. Canada Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
- 4.6.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Antibiotic Resistance Market Outlook, 2018 - 2031

5.1. Europe Antibiotic Resistance Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Beta Lactam Antibiotic
  - 5.1.1.2. Cephalosporins
  - 5.1.1.3. Quinolones Antibiotics
  - 5.1.1.4. Macrolide Antibiotics
  - 5.1.1.5. Tetracyclines
  - 5.1.1.6. Oxazolidinones
  - 5.1.1.7. Others
5.2. Europe Antibiotic Resistance Market Outlook, by Pathogen, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Staphylococcus aureus
  - 5.2.1.2. Streptococcus pneumonia
  - 5.2.1.3. Neisseria gonorrhoeae
  - 5.2.1.4. Enterococcus faecium
  - 5.2.1.5. Escherichia coli
  - 5.2.1.6. Klebsiella Pneumonia
  - 5.2.1.7. Shigella
  - 5.2.1.8. Clostridium difficile
  - 5.2.1.9. Others
5.3. Europe Antibiotic Resistance Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Community Acquired Bacterial Pneumonia (CABP)
  - 5.3.1.2. Hospitals Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
  - 5.3.1.3. Complicated Urinary Tract Infections (CUTI)
  - 5.3.1.4. Complicated Intra-Abdominal Infections (CIAI)
  - 5.3.1.5. Blood Stream Infections (BSI)
  - 5.3.1.6. Abdominal Infection and Diarrhoea (Clostridium difficile infections (CDI) & Shigella)
  - 5.3.1.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  - 5.3.1.8. Drug Resistant Gonorrhoeae
5.4. Europe Antibiotic Resistance Market Outlook, by Mechanism of Action, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Cell Wall Synthesis Inhibitors
  - 5.4.1.2. Protein Synthesis Inhibitors
  - 5.4.1.3. DNA Synthesis Inhibitors
  - 5.4.1.4. RNA Synthesis Inhibitors
  - 5.4.1.5. Others
5.5. Europe Antibiotic Resistance Market Outlook, by Distribution channel, Value (US$ Bn), 2018 - 2031
- 5.5.1. Key Highlights
  - 5.5.1.1. Hospitals Pharmacies
  - 5.5.1.2. Retail Pharmacies
  - 5.5.1.3. Online Pharmacies
- 5.5.2. BPS Analysis/Market Attractiveness Analysis
5.6. Europe Antibiotic Resistance Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.6.1. Key Highlights
  - 5.6.1.1. Germany Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.6.1.2. Germany Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 5.6.1.3. Germany Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 5.6.1.4. Germany Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 5.6.1.5. Germany Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 5.6.1.6. U.K. Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.6.1.7. U.K. Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 5.6.1.8. U.K. Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 5.6.1.9. U.K. Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 5.6.1.10. U.K. Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 5.6.1.11. France Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.6.1.12. France Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 5.6.1.13. France Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 5.6.1.14. France Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 5.6.1.15. France Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 5.6.1.16. Italy Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.6.1.17. Italy Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 5.6.1.18. Italy Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 5.6.1.19. Italy Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 5.6.1.20. Italy Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 5.6.1.21. Turkey Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.6.1.22. Turkey Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 5.6.1.23. Turkey Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 5.6.1.24. Turkey Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 5.6.1.25. Turkey Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 5.6.1.26. Russia Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.6.1.27. Russia Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 5.6.1.28. Russia Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 5.6.1.29. Russia Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 5.6.1.30. Russia Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 5.6.1.31. Rest of Europe Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.6.1.32. Rest of Europe Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 5.6.1.33. Rest of Europe Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 5.6.1.34. Rest of Europe Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 5.6.1.35. Rest of Europe Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
- 5.6.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Antibiotic Resistance Market Outlook, 2018 - 2031

6.1. Asia Pacific Antibiotic Resistance Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Beta Lactam Antibiotic
  - 6.1.1.2. Cephalosporins
  - 6.1.1.3. Quinolones Antibiotics
  - 6.1.1.4. Macrolide Antibiotics
  - 6.1.1.5. Tetracyclines
  - 6.1.1.6. Oxazolidinones
  - 6.1.1.7. Others
6.2. Asia Pacific Antibiotic Resistance Market Outlook, by Pathogen, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Staphylococcus aureus
  - 6.2.1.2. Streptococcus pneumonia
  - 6.2.1.3. Neisseria gonorrhoeae
  - 6.2.1.4. Enterococcus faecium
  - 6.2.1.5. Escherichia coli
  - 6.2.1.6. Klebsiella Pneumonia
  - 6.2.1.7. Shigella
  - 6.2.1.8. Clostridium difficile
  - 6.2.1.9. Others
6.3. Asia Pacific Antibiotic Resistance Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Community Acquired Bacterial Pneumonia (CABP)
  - 6.3.1.2. Hospitals Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
  - 6.3.1.3. Complicated Urinary Tract Infections (CUTI)
  - 6.3.1.4. Complicated Intra-Abdominal Infections (CIAI)
  - 6.3.1.5. Blood Stream Infections (BSI)
  - 6.3.1.6. Abdominal Infection and Diarrhoea (Clostridium difficile infections (CDI) & Shigella)
  - 6.3.1.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  - 6.3.1.8. Drug Resistant Gonorrhoeae
6.4. Asia Pacific Antibiotic Resistance Market Outlook, by Mechanism of Action, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. Cell Wall Synthesis Inhibitors
  - 6.4.1.2. Protein Synthesis Inhibitors
  - 6.4.1.3. DNA Synthesis Inhibitors
  - 6.4.1.4. RNA Synthesis Inhibitors
  - 6.4.1.5. Others
6.5. Asia Pacific Antibiotic Resistance Market Outlook, by Distribution channel, Value (US$ Bn), 2018 - 2031
- 6.5.1. Key Highlights
  - 6.5.1.1. Hospitals Pharmacies
  - 6.5.1.2. Retail Pharmacies
  - 6.5.1.3. Online Pharmacies
- 6.5.2. BPS Analysis/Market Attractiveness Analysis
6.6. Asia Pacific Antibiotic Resistance Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.6.1. Key Highlights
  - 6.6.1.1. China Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.6.1.2. China Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 6.6.1.3. China Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 6.6.1.4. China Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 6.6.1.5. China Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 6.6.1.6. Japan Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.6.1.7. Japan Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 6.6.1.8. Japan Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 6.6.1.9. Japan Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 6.6.1.10. Japan Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 6.6.1.11. South Korea Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.6.1.12. South Korea Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 6.6.1.13. South Korea Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 6.6.1.14. South Korea Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 6.6.1.15. South Korea Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 6.6.1.16. India Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.6.1.17. India Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 6.6.1.18. India Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 6.6.1.19. India Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 6.6.1.20. India Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 6.6.1.21. Southeast Asia Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.6.1.22. Southeast Asia Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 6.6.1.23. Southeast Asia Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 6.6.1.24. Southeast Asia Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 6.6.1.25. Southeast Asia Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 6.6.1.26. Rest of Asia Pacific Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.6.1.27. Rest of Asia Pacific Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 6.6.1.28. Rest of Asia Pacific Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 6.6.1.29. Rest of Asia Pacific Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 6.6.1.30. Rest of Asia Pacific Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
- 6.6.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Antibiotic Resistance Market Outlook, 2018 - 2031

7.1. Latin America Antibiotic Resistance Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Beta Lactam Antibiotic
  - 7.1.1.2. Cephalosporins
  - 7.1.1.3. Quinolones Antibiotics
  - 7.1.1.4. Macrolide Antibiotics
  - 7.1.1.5. Tetracyclines
  - 7.1.1.6. Oxazolidinones
  - 7.1.1.7. Others
7.2. Latin America Antibiotic Resistance Market Outlook, by Pathogen, Value (US$ Bn), 2018 - 2031
7.3. Latin America Antibiotic Resistance Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Community Acquired Bacterial Pneumonia (CABP)
  - 7.3.1.2. Hospitals Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
  - 7.3.1.3. Complicated Urinary Tract Infections (CUTI)
  - 7.3.1.4. Complicated Intra-Abdominal Infections (CIAI)
  - 7.3.1.5. Blood Stream Infections (BSI)
  - 7.3.1.6. Abdominal Infection and Diarrhoea (Clostridium difficile infections (CDI) & Shigella)
  - 7.3.1.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  - 7.3.1.8. Drug Resistant Gonorrhoeae
7.4. Latin America Antibiotic Resistance Market Outlook, by Mechanism of Action, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Cell Wall Synthesis Inhibitors
  - 7.4.1.2. Protein Synthesis Inhibitors
  - 7.4.1.3. DNA Synthesis Inhibitors
  - 7.4.1.4. RNA Synthesis Inhibitors
  - 7.4.1.5. Others
7.5. Latin America Antibiotic Resistance Market Outlook, by Distribution channel, Value (US$ Bn), 2018 - 2031
- 7.5.1. Key Highlights
  - 7.5.1.1. Hospitals Pharmacies
  - 7.5.1.2. Retail Pharmacies
  - 7.5.1.3. Online Pharmacies
- 7.5.2. BPS Analysis/Market Attractiveness Analysis
7.6. Latin America Antibiotic Resistance Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.6.1. Key Highlights
  - 7.6.1.1. Brazil Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.6.1.2. Brazil Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 7.6.1.3. Brazil Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 7.6.1.4. Brazil Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 7.6.1.5. Brazil Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 7.6.1.6. Mexico Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.6.1.7. Mexico Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 7.6.1.8. Mexico Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 7.6.1.9. Mexico Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 7.6.1.10. Mexico Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 7.6.1.11. Argentina Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.6.1.12. Argentina Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 7.6.1.13. Argentina Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 7.6.1.14. Argentina Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 7.6.1.15. Argentina Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 7.6.1.16. Rest of Latin America Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.6.1.17. Rest of Latin America Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 7.6.1.18. Rest of Latin America Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 7.6.1.19. Rest of Latin America Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 7.6.1.20. Rest of Latin America Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
- 7.6.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Antibiotic Resistance Market Outlook, 2018 - 2031

8.1. Middle East & Africa Antibiotic Resistance Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Beta Lactam Antibiotic
  - 8.1.1.2. Cephalosporins
  - 8.1.1.3. Quinolones Antibiotics
  - 8.1.1.4. Macrolide Antibiotics
  - 8.1.1.5. Tetracyclines
  - 8.1.1.6. Oxazolidinones
  - 8.1.1.7. Others
8.2. Middle East & Africa Antibiotic Resistance Market Outlook, by Pathogen, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Staphylococcus aureus
  - 8.2.1.2. Streptococcus pneumonia
  - 8.2.1.3. Neisseria gonorrhoeae
  - 8.2.1.4. Enterococcus faecium
  - 8.2.1.5. Escherichia coli
  - 8.2.1.6. Klebsiella Pneumonia
  - 8.2.1.7. Shigella
  - 8.2.1.8. Clostridium difficile
  - 8.2.1.9. Others
8.3. Middle East & Africa Antibiotic Resistance Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Community Acquired Bacterial Pneumonia (CABP)
  - 8.3.1.2. Hospitals Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
  - 8.3.1.3. Complicated Urinary Tract Infections (CUTI)
  - 8.3.1.4. Complicated Intra-Abdominal Infections (CIAI)
  - 8.3.1.5. Blood Stream Infections (BSI)
  - 8.3.1.6. Abdominal Infection and Diarrhoea (Clostridium difficile infections (CDI) & Shigella)
  - 8.3.1.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  - 8.3.1.8. Drug Resistant Gonorrhoeae
8.4. Middle East & Africa Antibiotic Resistance Market Outlook, by Mechanism of Action, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. Cell Wall Synthesis Inhibitors
  - 8.4.1.2. Protein Synthesis Inhibitors
  - 8.4.1.3. DNA Synthesis Inhibitors
  - 8.4.1.4. RNA Synthesis Inhibitors
  - 8.4.1.5. Others
8.5. Middle East & Africa Antibiotic Resistance Market Outlook, by Distribution channel, Value (US$ Bn), 2018 - 2031
- 8.5.1. Key Highlights
  - 8.5.1.1. Hospitals Pharmacies
  - 8.5.1.2. Retail Pharmacies
  - 8.5.1.3. Online Pharmacies
- 8.5.2. BPS Analysis/Market Attractiveness Analysis
8.6. Middle East & Africa Antibiotic Resistance Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.6.1. Key Highlights
  - 8.6.1.1. GCC Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.6.1.2. GCC Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 8.6.1.3. GCC Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 8.6.1.4. GCC Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 8.6.1.5. GCC Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 8.6.1.6. South Africa Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.6.1.7. South Africa Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 8.6.1.8. South Africa Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 8.6.1.9. South Africa Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 8.6.1.10. South Africa Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 8.6.1.11. Egypt Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.6.1.12. Egypt Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 8.6.1.13. Egypt Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 8.6.1.14. Egypt Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 8.6.1.15. Egypt Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 8.6.1.16. Nigeria Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.6.1.17. Nigeria Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 8.6.1.18. Nigeria Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 8.6.1.19. Nigeria Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 8.6.1.20. Nigeria Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
  - 8.6.1.21. Rest of Middle East & Africa Antibiotic Resistance Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.6.1.22. Rest of Middle East & Africa Antibiotic Resistance Market by Pathogen, Value (US$ Bn), 2018 - 2031
  - 8.6.1.23. Rest of Middle East & Africa Antibiotic Resistance Market by Disease, Value (US$ Bn), 2018 - 2031
  - 8.6.1.24. Rest of Middle East & Africa Antibiotic Resistance Market by Mechanism of Action, Value (US$ Bn), 2018 - 2031
  - 8.6.1.25. Rest of Middle East & Africa Antibiotic Resistance Market by Distribution channel, Value (US$ Bn), 2018 - 2031
- 8.6.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Species vs by Pathogen Heat map
9.2. Manufacturer vs by Pathogen Heat map
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
- 9.5.1. Thermo Fisher Scientific, Inc.
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Product Portfolio
  - 9.5.1.3. Financial Overview
  - 9.5.1.4. Business Strategies and Development
- 9.5.2. Merck KgaA
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Product Portfolio
  - 9.5.2.3. Financial Overview
  - 9.5.2.4. Business Strategies and Development
- 9.5.3. Bio-Rad Laboratories, Inc.
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Product Portfolio
  - 9.5.3.3. Financial Overview
  - 9.5.3.4. Business Strategies and Development
- 9.5.4. Takara Bio, Inc.
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Product Portfolio
  - 9.5.4.3. Financial Overview
  - 9.5.4.4. Business Strategies and Development
- 9.5.5. QIAGEN N.V.
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Product Portfolio
  - 9.5.5.3. Financial Overview
  - 9.5.5.4. Business Strategies and Development
- 9.5.6. Pall Corporation
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Product Portfolio
  - 9.5.6.3. Financial Overview
  - 9.5.6.4. Business Strategies and Development
- 9.5.7. Eppendorf Corporate
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Product Portfolio
  - 9.5.7.3. Financial Overview
  - 9.5.7.4. Business Strategies and Development
- 9.5.8. Tarsons Products PVT. LTD.
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Product Portfolio
  - 9.5.8.3. Financial Overview
  - 9.5.8.4. Business Strategies and Development
- 9.5.9. Applied Biological Materials Inc.
  - 9.5.9.1. Company Overview
  - 9.5.9.2. Product Portfolio
  - 9.5.9.3. Financial Overview
  - 9.5.9.4. Business Strategies and Development
- 9.5.10. Greiner AG
  - 9.5.10.1. Company Overview
  - 9.5.10.2. Product Portfolio
  - 9.5.10.3. Financial Overview
  - 9.5.10.4. Business Strategies and Development
- 9.5.11. Brooks Life Sciences
  - 9.5.11.1. Company Overview
  - 9.5.11.2. Product Portfolio
  - 9.5.11.3. Financial Overview
  - 9.5.11.4. Business Strategies and Development
- 9.5.12. Corning Incorporated
  - 9.5.12.1. Company Overview
  - 9.5.12.2. Product Portfolio
  - 9.5.12.3. Financial Overview
  - 9.5.12.4. Business Strategies and Development
- 9.5.13. Cytiva
  - 9.5.13.1. Company Overview
  - 9.5.13.2. Product Portfolio
  - 9.5.13.3. Financial Overview
  - 9.5.13.4. Business Strategies and Development
- 9.5.14. PerkinElmer
  - 9.5.14.1. Company Overview
  - 9.5.14.2. Product Portfolio
  - 9.5.14.3. Financial Overview
  - 9.5.14.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations